Beacon Financial Group reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 82.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,970 shares of the company's stock after selling 9,405 shares during the period. Beacon Financial Group's holdings in Cencora were worth $548,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Hickory Asset Management Inc. purchased a new stake in Cencora during the 4th quarter worth approximately $572,000. Vontobel Holding Ltd. boosted its holdings in shares of Cencora by 46.9% during the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after purchasing an additional 1,995 shares during the last quarter. Portfolio Design Labs LLC boosted its holdings in shares of Cencora by 76.9% during the 4th quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock worth $2,479,000 after purchasing an additional 4,794 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Cencora by 4.4% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,575 shares of the company's stock worth $6,420,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Latitude Advisors LLC acquired a new position in shares of Cencora during the 4th quarter worth approximately $559,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Cencora
In other news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer now owns 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,253 shares of company stock valued at $11,102,417. 10.80% of the stock is currently owned by company insiders.
Cencora Stock Down 0.4%
Shares of NYSE COR opened at $287.91 on Friday. The firm has a market cap of $55.80 billion, a price-to-earnings ratio of 40.95, a PEG ratio of 1.31 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35. The business's 50 day moving average is $286.06 and its two-hundred day moving average is $259.82.
Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.80 earnings per share. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.
Analysts Set New Price Targets
Several research analysts have recently weighed in on COR shares. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $274.00 to $337.00 in a report on Tuesday. Robert W. Baird boosted their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Finally, Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $306.91.
Read Our Latest Report on Cencora
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
